| P50 | author | John Mascarenhas | Q60320904 |
| | Joseph Tripodi | Q60320908 |
| P2093 | author name string | Xiaoli Wang | |
| | Yan Li | |
| | Min Lu | |
| | Ronald Hoffman | |
| | Vesna Najfeld | |
| | Marina Kremyanskaya | |
| | Goar Mosoyan | |
| P2860 | cites work | Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha | Q72490598 |
| | Role of serum-free medium in the ex vivo expansion of human cord blood hematopoietic stem cells | Q73607415 |
| | Long-term effects of the treatment of polycythemia vera with recombinant interferon-alpha | Q79805117 |
| | p53 lesions in leukemic transformation | Q83352019 |
| | In vivo activation of the p53 pathway by small-molecule antagonists of MDM2 | Q27642888 |
| | Dissecting specificity in the Janus kinases: the structures of JAK-specific inhibitors complexed to the JAK1 and JAK2 protein tyrosine kinase domains | Q27654637 |
| | High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a | Q27824871 |
| | CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients | Q28238474 |
| | Molecular pathogenesis of Philadelphia chromosome negative myeloproliferative disorders | Q28295823 |
| | Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis | Q33391880 |
| | Safety and efficacy of TG101348, a selective JAK2 inhibitor, in myelofibrosis | Q33393587 |
| | The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors | Q33613105 |
| | IARC p53 mutation database: a relational database to compile and analyze p53 mutations in human tumors and cell lines. International Agency for Research on Cancer | Q33711143 |
| | CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms | Q33944270 |
| | JAK inhibitors in myeloproliferative neoplasms: rationale, current data and perspective | Q33956483 |
| | Type I interferon receptors: biochemistry and biological functions. | Q34628239 |
| | Interferon-alpha targets JAK2V617F-positive hematopoietic progenitor cells and acts through the p38 MAPK pathway | Q34949540 |
| | Polycythemia vera: myths, mechanisms, and management | Q34977300 |
| | Clinical and scientific advances in the Philadelphia-chromosome negative chronic myeloproliferative disorders | Q34996327 |
| | Resveratrol, through NF-Y/p53/Sin3/HDAC1 complex phosphorylation, inhibits estrogen receptor alpha gene expression via p38MAPK/CK2 signaling in human breast cancer cells | Q35225077 |
| | STAT-1: a novel regulator of apoptosis | Q35641356 |
| | STAT1 as a key modulator of cell death | Q36644901 |
| | MDM2 inhibitors for cancer therapy | Q36663493 |
| | Interferon-alpha therapy in bcr-abl-negative myeloproliferative neoplasms. | Q37289795 |
| | Transcriptionally active Stat1 is required for the antiproliferative effects of both interferon alpha and interferon gamma | Q37432208 |
| | Prospect of JAK2 inhibitor therapy in myeloproliferative neoplasms | Q37483993 |
| | p53 in chronic myelogenous leukemia in acute phase | Q37550931 |
| | JAK2(V617F) negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms | Q39501601 |
| | A Small-Molecule Inhibitor of MDMX Activates p53 and Induces Apoptosis | Q39632042 |
| | SIRT2 down-regulation in HeLa can induce p53 accumulation via p38 MAPK activation-dependent p300 decrease, eventually leading to apoptosis | Q39634508 |
| | Activation of STAT1 is required for interferon-alpha-mediated cell death | Q39645745 |
| | Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents | Q40054238 |
| | Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. | Q41199732 |
| | STAT-1 interacts with p53 to enhance DNA damage-induced apoptosis | Q42452343 |
| | The structural basis of Janus kinase 2 inhibition by a potent and specific pan-Janus kinase inhibitor | Q46713383 |
| | MDM2 and MDMX in cancer and development. | Q51889545 |
| | N-ras and p53 gene mutations in Japanese patients with myeloproliferative disorders. | Q52547649 |
| | Lupulone triggers p38 MAPK-controlled activation of p53 and of the TRAIL receptor apoptotic pathway in human colon cancer-derived metastatic cells. | Q54594373 |
| | Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera. | Q54598140 |
| | Clinical-scale cultures of cord blood CD34(+) cells to amplify committed progenitors and maintain stem cell activity. | Q54615281 |
| | Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera | Q58416020 |
| P433 | issue | 15 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | polycythemia vera | Q948318 |
| P1104 | number of pages | 8 | |
| P304 | page(s) | 3098-3105 | |
| P577 | publication date | 2012-08-07 | |
| P1433 | published in | Blood | Q885070 |
| P1476 | title | Combination treatment in vitro with Nutlin, a small-molecule antagonist of MDM2, and pegylated interferon-α 2a specifically targets JAK2V617F-positive polycythemia vera cells | |
| P478 | volume | 120 | |